PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.
Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.
A 30-year-old female with telogen effluvium and androgenetic alopecia is using spironolactone, oral minoxidil, vitamin D, iron sulfate, and a hairmax laser band. She seeks recommendations for a dermastamp or derma roller, advised to use no higher than 0.5 mm.
A user shared impressive hair regrowth results after three months of taking 1mg daily of finasteride. Other users commented on their experiences and the effectiveness of different treatments like minoxidil and dutasteride.
A 17-year-old is concerned about hair loss and questions his dermatologist's advice against using finasteride due to age. The dermatologist recommended a serum with aloe vera, saw palmetto, biotin, and dexpanthenol, but the user is skeptical and considers using minoxidil instead.
A user shared progress pictures showing significant hair growth over 3.5 months using Dutasteride, Minoxidil, and microneedling. They are pleased with the results but unsure how to style their growing hair.
A user is concerned that finasteride isn't working after 4 months and is considering switching to dutasteride due to severe hair loss. Others suggest continuing finasteride, adding minoxidil, and being patient.
Peptides like TB500, KPV, GHK-CU, and BPC-157 are overhyped for hair growth with limited proven effectiveness in humans. Combining peptides with delivery methods like iontophoresis and sonophoresis shows promise, but many claims remain unproven.
A user shared their 3-month hair loss treatment progress using 5% minoxidil, 1mg finasteride, and occasional nizoral. They noted significant progress and plan to continue treatments, with another update at the 6-month mark.